Swiss Cancer Institute / Astellas & AstraZeneca Translational GU Oncology Research Award

• Dr. Clémentine Le Magnen, University Hospital Basel
• Dr. med. Mohamed Shelan, Inselspital Bern
• Prof. Dr. med. Jean-Philippe Theurillat, Institute of Oncolgy Research IOR Bellinzona
• Dr. med. Petros Tsantoulis, Les hôpitaux universitaires de Genève HUG

Applicants must have their primary place of work in Switzerland. Doctoral students, postdoctoral researchers and clinically active scientists (physician-scientists) who are involved in translational or clinical research are eligible.

• Projects should be translational in nature. They should be aimed at translating basic research 
  discoveries into the clinic. Possible projects could include, but are not limited to:

• • Development of novel treatments for GU cancers focused on small molecules, biologics, or radioligand therapies
  • Development of diagnostic modalities for GU cancers
  • Development of novel prevention strategies for GU cancers
• Approaches can include preclinical, animal, human tissue, and/or human studies
• Purely basic research projects are out of scope.
• Must be conducted in Switzerland, but can be part of larger collaborative projects. In the case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect.
• Only costs that are still occurring can be covered by the award.

Applications must be written in English and include the following information:

• Curriculum vitae of the candidate
• The abstract of not more than 300 words should include a project title, the rationale, aim of the project, and how this research will be translated into the clinic

Project proposals will only be evaluated if they are deemed to be eligible and feasible according to the project scope defined above. Evaluation will be based on the presentation/abstract and on the following criteria: 

•  Estimated impact on GU cancer outcomes
• Translatability of the project
• Novelty of the project
• Oral presentation skills: ability to answer questions and defend the project

Please submit your application by April 27, 2026.

Applications must be submitted electronically to the Swiss Cancer Institute, events@swisscancerinstitute.ch.

After the submission deadline, the Scientific Committee will carefully review all submitted applications and invite 6 to 8 applicants to present their project at the Translational Urogenital Network Meeting on June 18/19, 2026 in Baden AG. Accommodation will be provided for all invited applicants. Following all presentations, the Scientific Committee will select the winning project.

In collaboration with Astellas and AstraZeneca